Please assess the completion status of the following clinical trial:

Trial Title: A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a body mass index (BMI) of 18.0-30.0 kg/m\^2, inclusive, at Visit 1 and Visit 2~* Subject meets the DSM-5 criteria for a primary diagnosis of schizophrenia~* Subject is appropriate for outpatient treatment; has no hospitalizations for acute exacerbations of schizophrenia within 6 months before Visit 1~* Subject has maintained a stable body weight (change \</= 5%) for at least 3 months prior to Visit 1 based on self-report~* Additional criteria may apply~Exclusion Criteria:~* Subject has any of the following psychiatric conditions per DSM-5 criteria:~* Diagnosis of schizoaffective disorder or bipolar I or II disorder, or current, untreated or unstable major depressive disorder~* Clinically significant cognitive difficulties present within the past 2 years that could interfere with participation in the study~* Drug-induced or toxic psychosis~* Any other psychiatric condition that could interfere with participation in the study~* Subject poses a current suicide risk at Visit 1 or Visit 2 in the opinion of the investigator~* Subject has inflammatory bowel disease or any other gastrointestinal disorder associated with weight loss, anorexia nervosa, or binge eating disorder~* Additional criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- ALKS 3831 (Type: EXPERIMENTAL): Administered as a coated bilayer tablet
- Olanzapine (Type: ACTIVE_COMPARATOR): Administered as a coated bilayer tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).